CU24299B1 - Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico - Google Patents
Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmicoInfo
- Publication number
- CU24299B1 CU24299B1 CUP2013000110A CU20130110A CU24299B1 CU 24299 B1 CU24299 B1 CU 24299B1 CU P2013000110 A CUP2013000110 A CU P2013000110A CU 20130110 A CU20130110 A CU 20130110A CU 24299 B1 CU24299 B1 CU 24299B1
- Authority
- CU
- Cuba
- Prior art keywords
- growth factor
- receptors
- type
- epidermal growth
- compositions based
- Prior art date
Links
- 239000000203 mixture Substances 0.000 title abstract 3
- 102000009024 Epidermal Growth Factor Human genes 0.000 title 1
- 101800003838 Epidermal growth factor Proteins 0.000 title 1
- 229940116977 epidermal growth factor Drugs 0.000 title 1
- VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 title 1
- 206010028980 Neoplasm Diseases 0.000 abstract 2
- 101100123850 Caenorhabditis elegans her-1 gene Proteins 0.000 abstract 1
- 101150029707 ERBB2 gene Proteins 0.000 abstract 1
- -1 GM3 ganglioside Chemical class 0.000 abstract 1
- 102000009465 Growth Factor Receptors Human genes 0.000 abstract 1
- 108010009202 Growth Factor Receptors Proteins 0.000 abstract 1
- 241000588650 Neisseria meningitidis Species 0.000 abstract 1
- 101710116435 Outer membrane protein Proteins 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 239000012634 fragment Substances 0.000 abstract 1
- 108010030416 proteoliposomes Proteins 0.000 abstract 1
- 238000007920 subcutaneous administration Methods 0.000 abstract 1
- 229960005486 vaccine Drugs 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001106—Her-2/neu/ErbB2, Her-3/ErbB3 or Her 4/ErbB4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001169—Tumor associated carbohydrates
- A61K39/001171—Gangliosides, e.g. GM2, GD2 or GD3
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/04—Immunostimulants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/545—Medicinal preparations containing antigens or antibodies characterised by the dose, timing or administration schedule
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55505—Inorganic adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55555—Liposomes; Vesicles, e.g. nanoparticles; Spheres, e.g. nanospheres; Polymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
- A61K2039/55511—Organic adjuvants
- A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/70—Multivalent vaccine
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Immunology (AREA)
- Oncology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Microbiology (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Cell Biology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Communicable Diseases (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Peptides Or Proteins (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
Priority Applications (27)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CUP2013000110A CU24299B1 (es) | 2013-08-02 | 2013-08-02 | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
| UAA201602000A UA116154C2 (uk) | 2013-08-02 | 2014-01-08 | Бівалентна вакцинна композиція та її застосування для лікування злоякісних пухлин |
| ARP140102872A AR097172A1 (es) | 2013-08-02 | 2014-07-31 | Composiciones vacunales bivalentes y su uso para la terapia de tumores |
| CN201480042561.6A CN105407916A (zh) | 2013-08-02 | 2014-08-01 | 二价疫苗组合物以及其用于治疗肿瘤的用途 |
| MYPI2016700376A MY194889A (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumors |
| AU2014298978A AU2014298978B2 (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumours |
| KR1020167000152A KR20160018665A (ko) | 2013-08-02 | 2014-08-01 | 이가 백신 조성물 및 종양 치료를 위한 이의 용도 |
| US14/908,635 US20160166667A1 (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumors |
| PCT/CU2014/000004 WO2015014327A1 (es) | 2013-08-02 | 2014-08-01 | Composiciones vacunales bivalentes y su uso para la terapia de tumores |
| EP14758073.2A EP3028714B1 (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumours |
| CA2916552A CA2916552C (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumors |
| NZ716579A NZ716579B2 (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumours |
| EA201690309A EA034194B1 (ru) | 2013-08-02 | 2014-08-01 | Вакцинная композиция и ее применение для лечения злокачественных опухолей |
| JP2016530348A JP6479002B2 (ja) | 2013-08-02 | 2014-08-01 | 二価ワクチン組成物及び腫瘍を治療するためのその使用 |
| TN2015000557A TN2015000557A1 (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumours |
| MX2016001459A MX2016001459A (es) | 2013-08-02 | 2014-08-01 | Composiciones vacunales bivalentes y su uso para la terapia de tumores. |
| ES14758073T ES2894075T3 (es) | 2013-08-02 | 2014-08-01 | Composiciones de vacunas divalentes y el uso de las mismas para el tratamiento de tumores |
| TW103126421A TWI554281B (zh) | 2013-08-02 | 2014-08-01 | 二價疫苗組成物及彼於腫瘤治療上之用途 |
| SG11201600084WA SG11201600084WA (en) | 2013-08-02 | 2014-08-01 | Divalent vaccine compositions and the use thereof for treating tumours |
| PE2016000083A PE20160174A1 (es) | 2013-08-02 | 2014-08-01 | Composiciones vacunales bivalentes y su uso para la terapia de tumores |
| BR112016002174-6A BR112016002174B1 (pt) | 2013-08-02 | 2014-08-01 | Composição de vacina |
| CL2015003706A CL2015003706A1 (es) | 2013-08-02 | 2015-12-22 | Composiciones vacunales bivalentes y su uso para la terapia de tumores |
| IL243879A IL243879B (en) | 2013-08-02 | 2016-01-31 | Bivalent vaccines and their use for the treatment of tumors |
| PH12016500224A PH12016500224A1 (en) | 2013-08-02 | 2016-02-02 | Divalent vaccine compositions and the use thereof for treating tumors |
| ZA2016/01328A ZA201601328B (en) | 2013-08-02 | 2016-02-26 | Divalent vaccine compositions and the use thereof for treating tumors |
| HK16108330.4A HK1220141A1 (zh) | 2013-08-02 | 2016-07-15 | 二價疫苗組合物以及其用於治療腫瘤的用途 |
| US16/398,334 US20190275132A1 (en) | 2013-08-02 | 2019-04-30 | Divalent vaccine compositions and the use thereof for treating tumors |
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CUP2013000110A CU24299B1 (es) | 2013-08-02 | 2013-08-02 | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| CU20130110A7 CU20130110A7 (es) | 2015-03-30 |
| CU24299B1 true CU24299B1 (es) | 2017-12-08 |
Family
ID=51453541
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CUP2013000110A CU24299B1 (es) | 2013-08-02 | 2013-08-02 | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico |
Country Status (24)
| Country | Link |
|---|---|
| US (2) | US20160166667A1 (xx) |
| EP (1) | EP3028714B1 (xx) |
| JP (1) | JP6479002B2 (xx) |
| KR (1) | KR20160018665A (xx) |
| CN (1) | CN105407916A (xx) |
| AR (1) | AR097172A1 (xx) |
| AU (1) | AU2014298978B2 (xx) |
| CA (1) | CA2916552C (xx) |
| CL (1) | CL2015003706A1 (xx) |
| CU (1) | CU24299B1 (xx) |
| EA (1) | EA034194B1 (xx) |
| ES (1) | ES2894075T3 (xx) |
| HK (1) | HK1220141A1 (xx) |
| IL (1) | IL243879B (xx) |
| MX (1) | MX2016001459A (xx) |
| MY (1) | MY194889A (xx) |
| PE (1) | PE20160174A1 (xx) |
| PH (1) | PH12016500224A1 (xx) |
| SG (1) | SG11201600084WA (xx) |
| TN (1) | TN2015000557A1 (xx) |
| TW (1) | TWI554281B (xx) |
| UA (1) | UA116154C2 (xx) |
| WO (1) | WO2015014327A1 (xx) |
| ZA (1) | ZA201601328B (xx) |
Families Citing this family (4)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP3597214A1 (en) | 2017-03-15 | 2020-01-22 | Centro de Inmunologia Molecular | Method for the treatment of patients with carcinomas |
| US12019073B2 (en) | 2017-03-15 | 2024-06-25 | Centro De Inmunologia Molecular | Method for the treatment of patients with carcinomas |
| CU24534B1 (es) * | 2017-11-06 | 2021-07-02 | Ct Inmunologia Molecular | Adyuvantes nano-particulados que contienen variantes sintéticas del gangliósido gm3 |
| CU20170173A7 (es) * | 2017-12-27 | 2019-11-04 | Ct Inmunologia Molecular | Nano-partículas que contienen el gangliósido gm3 como inmunomoduladoras |
Family Cites Families (3)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE4306697A1 (de) * | 1993-03-04 | 1994-09-08 | Merck Patent Gmbh | Mittel und Verfahren zur immunologischen Bestimmung von Diphenhydramin und dessen Metaboliten |
| PE20020572A1 (es) * | 2000-12-06 | 2002-07-31 | Centro Inmunologia Molecular | Preparaciones para potenciar la inmunogenicidad de antigenos poco inmunogenicos |
| EP2639299A1 (en) * | 2012-03-16 | 2013-09-18 | Invectys | Universal cancer peptides derived from telomerase |
-
2013
- 2013-08-02 CU CUP2013000110A patent/CU24299B1/xx unknown
-
2014
- 2014-01-08 UA UAA201602000A patent/UA116154C2/uk unknown
- 2014-07-31 AR ARP140102872A patent/AR097172A1/es unknown
- 2014-08-01 EA EA201690309A patent/EA034194B1/ru not_active IP Right Cessation
- 2014-08-01 EP EP14758073.2A patent/EP3028714B1/en active Active
- 2014-08-01 ES ES14758073T patent/ES2894075T3/es active Active
- 2014-08-01 WO PCT/CU2014/000004 patent/WO2015014327A1/es active Application Filing
- 2014-08-01 US US14/908,635 patent/US20160166667A1/en not_active Abandoned
- 2014-08-01 CN CN201480042561.6A patent/CN105407916A/zh active Pending
- 2014-08-01 AU AU2014298978A patent/AU2014298978B2/en active Active
- 2014-08-01 MY MYPI2016700376A patent/MY194889A/en unknown
- 2014-08-01 CA CA2916552A patent/CA2916552C/en active Active
- 2014-08-01 TW TW103126421A patent/TWI554281B/zh active
- 2014-08-01 KR KR1020167000152A patent/KR20160018665A/ko active Search and Examination
- 2014-08-01 SG SG11201600084WA patent/SG11201600084WA/en unknown
- 2014-08-01 TN TN2015000557A patent/TN2015000557A1/en unknown
- 2014-08-01 PE PE2016000083A patent/PE20160174A1/es not_active Application Discontinuation
- 2014-08-01 JP JP2016530348A patent/JP6479002B2/ja active Active
- 2014-08-01 MX MX2016001459A patent/MX2016001459A/es active IP Right Grant
-
2015
- 2015-12-22 CL CL2015003706A patent/CL2015003706A1/es unknown
-
2016
- 2016-01-31 IL IL243879A patent/IL243879B/en not_active IP Right Cessation
- 2016-02-02 PH PH12016500224A patent/PH12016500224A1/en unknown
- 2016-02-26 ZA ZA2016/01328A patent/ZA201601328B/en unknown
- 2016-07-15 HK HK16108330.4A patent/HK1220141A1/zh unknown
-
2019
- 2019-04-30 US US16/398,334 patent/US20190275132A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| CY1123258T1 (el) | Μεθοδος θεραπειας για τον καρκινο | |
| CL2016002359A1 (es) | Anticuerpos que se une al receptor de crecimiento epidermal humano (anti-egfr) y conjugados de anticuerpo anti-egfr y fármaco | |
| BR112016025035A2 (pt) | imunoterapia contra diversos tumores hematológicos, como a leucemia mieloide aguda (aml) | |
| CY1119410T1 (el) | Βελτιστοποιημενα μονοκλωνικα αντισωματα εναντι του αναστολεα της οδου του ιστικου παραγοντα (tfpi) | |
| PE20080663A1 (es) | Terapia tumoral con una combinacion de anticuerpos anti-her2 | |
| CY1121538T1 (el) | Μονοκλωνικα αντισωματα εναντι του αναστολεα του μονοπατιου ιστικου παραγοντα (tfpi) | |
| PE20181538A1 (es) | Nueva inmunoterapia contra diversos tumores como el cancer de pulmon, incluido el carcinoma de pulmon amicrocitico (nsclc) | |
| EA201790404A1 (ru) | Макропиноцитозирующие человеческие анти-cd46 антитела и таргетная терапия рака | |
| ECSP088753A (es) | Terapia tumoral con un anticuerpo contra el factor de crecimiento endotelial vascular y un anticuerpo contra el receptor del factor de crecimiento epitelial tipo 2 humano | |
| PH12021551208A1 (en) | Novel immunotherapy against several tumors, such as lung cancer, including nsclc | |
| BR112012030479A2 (pt) | terapia aprimorada de câncer baseada em antígenos associados a tumor derivados de ciclina d1 | |
| PE20160950A1 (es) | Biomarcadores de cancer y usos de los mismos | |
| UA118354C2 (uk) | Антитіло до рецептора колонієстимулювального фактора (кфс-1r) | |
| CU24299B1 (es) | Composiciones vacunales bivalentes basadas en los receptores de tipo 1 y 2 del factor de crecimiento epidérmico | |
| BR112015010039A2 (pt) | tratamento de câncer com pomalidomida em um individuo com disfunção renal | |
| BR112013029417A2 (pt) | composições de vacina de matriz proteica incluindo policátions | |
| CY1117579T1 (el) | Παραγωγα φαινυλιου-γουανiδiνης | |
| CY1122042T1 (el) | Συνθεση για χρηση στη θεραπεια του πονου που σχετιζεται με μεσοσπονδυλιο δισκο | |
| PE20181329A1 (es) | Metodos y composiciones para el tratamiento del sindrome de hunter | |
| AR118180A2 (es) | Inmunoterapia contra diversos tumores como el cáncer de pulmón, incluido el carcinoma de pulmón amicrocítico (nsclc) | |
| EA201491284A1 (ru) | ФАРМАЦЕВТИЧЕСКИЕ КОМПОЗИЦИИ ДЛЯ ЛЕЧЕНИЯ ОПУХОЛЕЙ, ЭКСПРЕССИРУЮЩИХ EGFR И N-ГЛИКОЛИЛГАНГЛИОЗИД GM3 (NEUGcGM3) | |
| PL423203A1 (pl) | Czynnik wzrostu do zastosowania w terapii przeciwnowotworowej dla pacjentów z nowotworami, w których przynajmniej część komórek wykazuje ekspresję EGFRvIII | |
| Johnstone et al. | Serglycin proteoglycan promotes progression and metastasis of triple-negative breast cancers | |
| EA202090816A2 (ru) | Новый метод иммунотерапии нескольких видов опухолей, таких как рак легкого, включая нмрл | |
| TH169737A (th) | องค์ประกอบวัคซีนชนิดไดวาเลนต์และการใช้พวกมันสำหรับการบำบัดเนื้องอก |